NCT05957510 2024-02-22
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials
Phase 2 Unknown
Guangdong Association of Clinical Trials
Sichuan University
Shanghai Henlius Biotech
Jiangsu HengRui Medicine Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
Taizhou HoudeAoke Biomedical Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China
ChineseAMS
Taizhou Hospital
University Hospital, Angers
National Cancer Institute (NCI)
Alaunos Therapeutics
Charite University, Berlin, Germany